Mallinckrodt Medical
This article was originally published in The Gray Sheet
Executive Summary
Forms alliance with OPTIMEDx to develop optical imaging agents for detection and localization of cancer cells. Seattle-based OPTIMEDx is developing a light-based imaging technology "designed to improve the detection and definition of certain cancer cells at an early stage," the companies said. Mallinckrodt will make an equity investment in OPTIMEDx, milestone payments, and product royalties. The company gains exclusive rights "to develop optical imaging agents for mammography" and non-exclusive rights to develop other cancer imaging agents